Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

After adjusting for confioundersUK cohort study (n=19 486 with COVID-19) reported ACE inhibitors (HR 0.71 95% CI 0.67- 0.74) and ARBs (0.63, 0.59-0.67) are associated with reduced risk of COVID-19 and neither are associated with increased risks of ICU care.

SPS commentary:

However, the study reported risk of COVID-19 disease associated with ACE inhibitors was higher in Caribbean (adjusted HR 1.05, 95% CI 0.87 to 1.28) and Black African (1.31, 1.08 to 1.59) groups vs Caucasians (0.66, 0.63 to 0.70).


A higher risk of COVID-19 with ARBs was seen for Black African (1.24, 0.99 to 1.58) vs Caucasians (0.56, 0.52 to 0.62).